Published 1 year ago

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement - ContraFect (NASDAQ:CFRX)

Summary by Ground News

Braxia Scientific Corp. is a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders. The Company has closed the first tranche of its non-brokered offering, resulting in the issuance of 13,658,524 units of the Company (each a "Unit") for aggregate proceeds of $751,218.83 (the "LIFE First Tranche"). Dr. Roger McIntyre, Chairman and CEO of Braxia, who subscribed, for 3,181,818 Units for aggregate gross proceeds of$175,000.

0 Articles

All

Left

Center

Right

Benzinga

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement - ContraFect (NASDAQ:CFRX)

YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to …

1 year ago·New York, United States

Read Full Article

Globe Newswire

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement

YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...

1 year ago

Read Full Article

News File Corp

Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement

Toronto, Ontario--(Newsfile Corp. - February 27, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, is pleased to announce that it has closed the first tranche of its non-brokered offering, as described in its press release of February 7, 2023 (the "LIFE Offering"), resu…

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated1 year agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement - ContraFect (NASDAQ:CFRX)

0 Articles

0 Articles

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement - ContraFect (NASDAQ:CFRX)

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement - ContraFect (NASDAQ:CFRX)

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement

ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement

Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement

Braxia Scientific Announces Closing of First Tranche of LIFE Offering and Concurrent Private Placement

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics